Home / Case Studies / Focus Stack Launch โ€” PNW Wellness Chain

Focus Stack Launch โ€” PNW Wellness Chain

A regional wellness chain in the Pacific Northwest introduced CBG gummies in a dedicated focus-stack shelf set. First reorder in 9 weeks. Added a second SKU on the reorder.

Buyer
4-location specialty wellness retail chain, Pacific Northwest. Mix of natural grocery-adjacent stores and standalone supplement shops. Existing cannabinoid SKUs limited to one general-wellness CBD gummy.
What they ordered
CBG Isolate 10mg ยท 800 units ยท white-label (buyer's existing brand applied to our stock formulation)
Lead time
3 weeks (artwork submitted at quote, production slot confirmed at deposit)
Reorder pattern
First reorder at 9 weeks (2,000 units, entering Growth tier). Added CBD+CBG 1:1 blend on the reorder.

What Worked

The buyer's category manager came to the initial conversation knowing they wanted CBG in the nootropic section rather than the general CBD section โ€” they had done their homework on shelf positioning before the first call. That clarity made the first order straightforward: one stock SKU, a proven formulation, white-label artwork they already had ready, and a Starter-tier volume that let all four stores get 200 units each to test.

Operationally, what worked was the shelf placement decision. The buyer physically moved their L-theanine and lion's mane SKUs to a dedicated "Focus" section facing and placed the CBG gummy between them. They built a simple shelf talker: "CBG โ€” Hemp's Daytime Cannabinoid." No efficacy claims, no medical language โ€” just category context that a customer could read in three seconds.

Staff training was done via a one-page fact sheet we provided with the order. Two key talking points for staff: (1) CBG is different from CBD โ€” same hemp plant, different cannabinoid, non-intoxicating, used by customers who want a daytime option. (2) For customers who already take CBD, CBG is the morning counterpart. That script gave staff enough to field the "what's CBG?" question without veering into efficacy claims.

Sell-through at all four locations was strong enough within six weeks that two locations were already asking the buyer to reorder. The 9-week reorder was driven by two locations near zero; the other two still had inventory. The buyer chose to consolidate the reorder across all four stores and move to a 2,000-unit order to hit the Growth tier pricing at $0.21/gummy versus $0.23 on the first order.

The second SKU added on the reorder was the CBD+CBG 1:1 Daytime blend. The buyer's logic: "We have customers who came back asking for something with CBD in it too. The 1:1 answers that question and keeps them in the category." The two-SKU set โ€” a CBG-isolate SKU for the committed CBG buyer and a 1:1 blend for the CBD-anchor buyer โ€” is now the standard configuration across all four stores.

What to Take From This Account

The pattern that made this account work: committed shelf placement in the nootropic section (not the CBD section), a short staff script that answered the two most common questions without making claims, and a willingness to start at 200 units per door and prove sell-through before committing to larger volume. The reorder was fast because the placement was right from the first week, not because the product sold itself.

For buyers in a similar position โ€” an existing CBD line, a nootropic or supplement section that is underdeveloped, and 4โ€“8 retail doors โ€” this is the template. One SKU at Starter tier. Committed placement. Basic staff training. Reorder in 8โ€“12 weeks. Add the second SKU on the reorder based on what customers asked for.

See Positioning CBG in the Focus Aisle and CBG vs CBD Margin Math for the strategic context behind this account's decisions.

Related

Start Your CBG Category the Same Way

Starter-tier quote, samples before you commit, and shelf-placement guidance included for new accounts.

Request CBG Wholesale Quote โ†’

Representative buyer profile โ€” anonymized for confidentiality. Operational details are typical for accounts at this volume tier. These statements have not been evaluated by the FDA. Our products are not intended to diagnose, treat, cure, or prevent any disease.